Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy Feb 21, 2019
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting Feb 12, 2019
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program Feb 6, 2019
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin Feb 4, 2019
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th Jan 29, 2019
Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference Jan 25, 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain Jan 23, 2019
Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated Jan 17, 2019
Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies Jan 16, 2019
